



# Correction: Elafibranor: First Approval

Hannah A. Blair<sup>1</sup>

Accepted: 23 August 2024  
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024

**Correction to:**  
**Blair, H.A. Elafibranor: First Approval.**  
*Drugs* (2024).  
<https://doi.org/10.1007/s40265-024-02075-8>

The original article has been corrected.

**Data availability** Not applicable.

**Section 2.1 Pharmacodynamics.** The third sentence of the second paragraph, which currently reads:

Although the in vitro pharmacology studies detected PPAR-gamma activation by elafibranor and GFT1007, animal toxicology studies demonstrated no adverse effects associated with activation of PPAR- $\gamma$  [6].

Should read:

Although the in vitro pharmacology studies detected PPAR- $\gamma$  activation by elafibranor and GFT1007, animal toxicology studies demonstrated no adverse effects associated with activation of PPAR- $\gamma$  [6].

**Table: Features and Properties of Elafibranor.** WHO ATC codes, which currently reads:  
A05AX (Other Drugs for Bile Therapy)

Should read:

A05AX06 (Other Drugs for Bile Therapy)

**Section 3 Current Status.** The reference for the last sentence should be [8] not [5]  
Elafibranor received a positive opinion in the EU in July 2024 for the treatment of PBC [8].

---

The original article can be found online at <https://doi.org/10.1007/s40265-024-02075-8>.

---

✉ Hannah A. Blair  
dru@adis.com

<sup>1</sup> Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand